{"id":"terlipressin-then-dummy","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Myocardial ischemia"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2135460","moleculeType":"Protein","molecularWeight":"1227.40"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Terlipressin & then Dummy","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:01:38.764213+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:01:51.354876+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:01:44.333019+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Terlipressin & then Dummy","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:01:44.712745+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Vasopressin V2 receptor binding agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:01:45.783078+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2135460/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:01:45.438212+00:00"}},"_dailymed":null,"aiSummary":"Terlipressin, marketed by Aga Khan University, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Terlipressin binds to vasopressin V1 receptors on blood vessels, causing splanchnic vasoconstriction and reducing portal venous pressure. This mechanism is particularly useful in portal hypertension-related bleeding and hepatorenal syndrome, where it improves renal perfusion and reduces variceal bleeding risk. The drug has greater V1 selectivity compared to native vasopressin, resulting in fewer systemic side effects.","oneSentence":"Terlipressin is a vasopressin analog that selectively activates V1 receptors on vascular smooth muscle to cause vasoconstriction and reduce portal pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:46.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:01:51.354952+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Acute variceal bleeding in portal hypertension"},{"name":"Hepatorenal syndrome (Type 1)"}]},"trialDetails":[{"nctId":"NCT00369694","phase":"PHASE4","title":"Short Course Terlipressin for Control of Acute Variceal Bleeding","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2006-08","conditions":"Hemorrhage, Esophageal Varices, Portal Hypertension","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2135460"},"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Novapressin"],"phase":"marketed","status":"active","brandName":"Terlipressin & then Dummy","genericName":"Terlipressin & then Dummy","companyName":"Aga Khan University","companyId":"aga-khan-university","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:01:51.354952+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}